KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage Parasites In Vitro. by Zeeman, A.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/138513
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
KAI407, a Potent Non-8-Aminoquinoline Compound That Kills
Plasmodium cynomolgi Early Dormant Liver Stage Parasites In Vitro
Anne-Marie Zeeman,a Sandra M. van Amsterdam,a Case W. McNamara,b Annemarie Voorberg-van der Wel,a Els J. Klooster,a
Alexander van den Berg,a Edmond J. Remarque,a David M. Plouffe,b Geert-Jan van Gemert,c Adrian Luty,c* Robert Sauerwein,c
Kerstin Gagaring,b Rachel Borboa,b Zhong Chen,b Kelli Kuhen,b Richard J. Glynne,b Arnab K. Chatterjee,b Advait Nagle,b
Jason Roland,b Elizabeth A. Winzeler,b Didier Leroy,d Brice Campo,d Thierry T. Diagana,e Bryan K. S. Yeung,e Alan W. Thomas,a
Clemens H. M. Kockena
Biomedical Primate Research Centre, Department of Parasitology, Rijswijk, The Netherlandsa; Genomics Institute of the Novartis Research Foundation, San Diego,
California, USAb; Medical Parasitology-268, MMB-NCMLS, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlandsc; Medicines for Malaria Venture,
Geneva, Switzerlandd; Novartis Institute for Tropical Diseases, Singaporee
Preventing relapses of Plasmodium vivaxmalaria through a radical cure depends on use of the 8-aminoquinoline primaquine,
which is associated with safety and compliance issues. For future malaria eradication strategies, new, safer radical curative com-
pounds that efficiently kill dormant liver stages (hypnozoites) will be essential. A new compound with potential radical cure ac-
tivity was identified using a low-throughput assay of in vitro-cultured hypnozoite forms of Plasmodium cynomolgi (an excellent
and accessible model for Plasmodium vivax). In this assay, primary rhesus hepatocytes are infected with P. cynomolgi sporozo-
ites, and exoerythrocytic development is monitored in the presence of compounds. Liver stage cultures are fixed after 6 days and
stained with anti-Hsp70 antibodies, and the relative proportions of small (hypnozoite) and large (schizont) forms relative to the
untreated controls are determined. This assay was used to screen a series of 18 known antimalarials and 14 new non-8-amino-
quinolines (preselected for blood and/or liver stage activity) in three-point 10-fold dilutions (0.1, 1, and 10Mfinal concentra-
tions). A novel compound, designated KAI407 showed an activity profile similar to that of primaquine (PQ), efficiently killing
the earliest stages of the parasites that become either primary hepatic schizonts or hypnozoites (50% inhibitory concentration
[IC50] for hypnozoites, KAI407, 0.69M, and PQ, 0.84M; for developing liver stages, KAI407, 0.64M, and PQ, 0.37M).
When given as causal prophylaxis, a single oral dose of 100 mg/kg of body weight prevented blood stage parasitemia in mice.
From these results, we conclude that KAI407 may represent a new compound class for P. vivaxmalaria prophylaxis and poten-
tially a radical cure.
Plasmodium vivax malaria causes between 70 million (1) and390 million (2) clinical cases per year (for a review, see refer-
ence 3). Although vivax malaria is often referred to as “benign,”
the disease is not mild, causing morbidity and mortality (4, 5). The
parasite, which is dependent on the Duffy antigen for red blood
cell (RBC) invasion, has been largely absent from West Africa,
where the population is primarily Duffy negative. However, re-
cent publications on P. vivax infections in Duffy-negative people
(6–8) suggest that P. vivax is making its way into other areas of
Africa, emphasizing the urgent need for new treatments.
One of the difficulties in fighting P. vivax stems from malaria
relapses, caused by activation of dormant liver stage parasites,
called hypnozoites (9). Currently, the only licensed drug for the
radical cure ofP. vivaxmalaria is primaquine (PQ), which is active
against blood stage parasites (asexual and gametocyte stages) and
liver stage parasites, including hypnozoites (10). However, PQ is
contraindicated in glucose-6-phosphate dehydrogenase (G6PD)-
deficient people, who can suffer from acute hemolytic anemia if
treated with PQ (11). The CDC-recommended treatment sched-
ule for PQ is 30 mg/day for 14 days (in non G6PD-deficient pa-
tients), limiting patient compliance, which could result in PQ re-
sistance (12, 13).
Until now, the in vivo Plasmodium cynomolgi/rhesus monkey
model has been the only model system exploited extensively to test
new antimalarials for radical cure activity (14, 15, 53), as P. cyno-
molgi is one of the few parasite species that forms hypnozoites.
Using this model, tafenoquine (16), elubaquine (also known as
bulaquine or CDRI80/53) (17), and NPC1161 (18) were identified
as antirelapse drugs, and these compounds are currently in pre-
clinical development. However, all are 8-aminoquinolines, and all
may have the same liabilities associated with PQ. Recently, Liu et
al. (19) described a new non-8-aminoquinoline compound with
radical cure properties in rhesus macaques, suggesting that new
chemical structures may also act on hypnozoites.
The identification of new chemical entities with potential rad-
ical cure activity has been hampered by the lack of an in vitro assay
to screen the parasite liver stages. We recently described the iden-
tification of imidazolopiperazines, which are active in vitro on
both Plasmodium blood and liver stages (20). The in vitro liver
stage assay used for screening is an image-based assay with
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HepG2-A16-CD81EGFP cells infected with Plasmodium yoelii
sporozoites. The assay can identify compounds that that arrest or
eliminate liver schizonts at various stages in development. Some
of these have subsequently been shown to be effective causal pro-
phylaxis agents in vivo. Although P. yoelii does not form hypno-
zoites, we surmise that compounds with activity on blood stages
and liver schizonts are more likely to act on the dormant liver
stages than randomly selected compounds or compounds with
blood stage activity only. We used this assay to preselect liver
stage-active compounds for evaluation on P. cynomolgi liver
stages. The assay described in this paper assesses compound activ-
ity on liver stage cultures in vitro using P. cynomolgi parasites and
is similar to assays previously described (21–24, 52) but is adapted
to be more efficient for in vitro drug screening by reducing culti-
vation time and utilizing a fully automatic readout. In this adapted
P. cynomolgi assay, the development of two distinct populations of
parasites is monitored in the cultures: small forms that resemble
hypnozoites both in appearance and in drug sensitivity profile and
developing liver stage schizonts (21). Recently, Dembele et al. (25)
have shown that the small forms can reactivate in vitro and can
grow out to mature liver schizonts, confirming the hypothesis that
these small forms are hypnozoites.
We evaluated the reproducibility of the P. cynomolgi in vitro
liver stage assay and used it in a low-throughput screen of com-
pounds with demonstrated antimalarial activity, identifying a new
potent non-8-aminoquinoline compound that, similar to prima-
quine, efficiently kills the early developmental forms of all liver
stages in vitro.
MATERIALS AND METHODS
Details of materials and methods are provided in the supplemental mate-
rial.
Generation of P. cynomolgi sporozoites. The Biomedical Primate
Research Centre (BPRC) is an AAALAC-certified institute. All rhesus ma-
caques (Macaca mulatta) used in this study were captive bred for research
purposes and were housed at the BPRC facilities in compliance with the
Dutch law on animal experiments, European directive 86/609/EEC, and
with the Standard for Humane Care and Use of Laboratory Animals by
Foreign institutions, identification number A5539-01, provided by the
National Institutes of Health (NIH). Prior to the start of experiments, all
protocols were approved by the local independent ethical committee, ac-
cording to Dutch law. Rhesus macaques were infected with 1  106 P.
cynomolgi M strain blood stage parasites and bled at peak parasitemia.
Approximately 300 female Anopheles stephensi mosquitoes strain Sind-
Kasur Nijmegen (Nijmegen University Medical Centre St. Radboud, De-
partment of Medical Microbiology) were fed with this blood (26).
Isolation and maintenance of primary rhesus hepatocytes. Rhesus
monkey hepatocytes were isolated from liver lobes, as described by
Guguen-Guillouzo et al. (27). Sporozoite infections were performed
within 3 days after hepatocyte isolation.
Sporozoite infection of primary rhesus hepatocytes. Sporozoite in-
oculation of primary rhesus hepatocytes was performed according to the
methods of Mazier et al. (28) and Dembele et al. (21). Hepatocytes were
washed with William’s B medium before adding 50,000 (96-well plates) or
90,000 (LabTek chamber slides) sporozoites/well. Cultures were kept at
37°C in 5% CO2 with regular medium changes. To evaluate the develop-
ment of P. cynomolgi liver stages, slides were fixed with cold methanol at
the indicated time points.
Drug assays on liver stage parasites. Compounds were diluted in
William’s B medium to 10, 1, and 0.1 M. Atovaquone, primaquine, and
medium only were used as controls. For 50% inhibitory concentration
(IC50) determination 2-fold serial dilutions (10 to 0.04 M final concen-
trations) were evaluated in duplicate. Statistical analyses were performed
as described in the supplemental material.
Visualization of liver stages. Intracellular P. cynomolgi malaria para-
sites were stained with the cross-reactive mouse polyclonal anti-Plasmo-
dium falciparum Hsp70 antibody and secondarily stained with fluorescein
isothiocyanate (FITC)-labeled goat anti-mouse IgG (21). Alternatively,
anti-P. cynomolgi Hsp70.1 (anti-PcyHsp70) and FITC-labeled goat anti-
rabbit Ig antibodies were used. Anti-P. cynomolgi Hsp70 antisera were
generated against part of the Hsp70 gene (amino acids 350 to 6860) (see
the supplemental material) (29). The number of exoerythrocytic forms
(EEFs) was determined for each well, using a Leica DMI6000 inverted
microscope. In later assays, the number of intracellular parasites was de-
termined using a high-content imaging system (Operetta; Perkin-Elmer).
Validation of the Operetta analysis was performed by comparing manual-
counting results of a number of plates with the outcome of Operetta
analysis. The parasitophorous vacuolar membrane (PVM) was visualized
using rabbit anti-P. cynomolgi Etramp serum generated against a mixture
of two peptides [(C)-IISPNDELKKEGLD and (C)-IMKHRKKERKE
MED, where C is cysteine, for coupling to column].
Criteria for distinguishing large and small EEF parasites. Based on
the limited information available about in vivo hypnozoite morphology,
we used the following definitions (30, 31): hypnozoite, a small (maximum
7-m-diameter), round intracellular parasite with 1 nucleus; developing
parasite, an intracellular parasite, larger than 7m and round or irregular
in shape, with more than 1 nucleus.
Sporozoite infection and atovaquone treatment of rhesus ma-
caques. Sporozoites were isolated according to the method of Mazier et al.
(28) and resuspended in phosphate-buffered saline (PBS); 6.37  106
sporozoites were injected into the vena saphena of two rhesus macaques
while under ketamine sedation. One of the animals was given atovaquone
(Mepron; 150 mg/ml; 10 mg/kg of body weight) via gavage immediately
after the sporozoite injection, followed by five daily oral dosings. The
other animal was treated with chloroquine (7.5 mg/kg) when blood stage
positive. Parasitemia was monitored via thin-film slides, which were fixed
with methanol and stained with Giemsa stain.
In vivo causal prophylaxis mouse model. Female ICR mice (8 or 9
weeks old) were randomized into groups of four mice. The animals in
each group were administered, via oral gavage, 20 or 100 mg/kg KAI407,
2.5 mg/kg atovaquone (in 0.5% [wt/vol] methylcellulose and 0.5% [vol/
vol] Tween 80 in distilled water), or vehicle only. Within 2 h of oral
dosing, all mice were inoculated intravenously via the lateral tail vein with
50  103 Plasmodium berghei ANKA luciferase sporozoites (32) in 5%
PBS. Blood smears were obtained on days 5 to 9, 12, 16, 23, and 30 post-
inoculation. Mice were observed twice daily for clinical signs of illness,
morbidity, and mortality. Animals were humanely euthanized when
blood parasitemia exceeded 2% or mice survived to day 30 (completion of
the prophylaxis study).
RESULTS
P. cynomolgi-infected rhesusmonkeys provide a reliable source
for sporozoite production.To overcome the bottleneck of access-
ing sufficient numbers of sporozoites from P. vivax for in vitro
hypnozoite drug assays, we set up a P. cynomolgi sporozoite pro-
duction platform. Due to the very reproducible blood stage infec-
tion pattern of rhesus monkeys (33), this proved to be a reliable
system for infecting A. stephensi mosquitoes, yielding an average
of 50,000 sporozoites per mosquito over 53 infections. A detailed
overview of blood stage parasitemia, transmission, oocyst count,
and sporozoite yield is given in Table S1 in the supplemental ma-
terial. Parasitemia ranged between 0.02 and 3.6% on the first day
of mosquito feeding (feed 1, usually 11 days after infection of a
rhesus monkey), and all but four transmissions were successful.
The oocyst count was positively correlated with blood stage para-
sitemia at the time of feed 1 (Spearman’s rho, 0.732; P  108)
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(see Fig. S1A in the supplemental material). Interestingly, the four
lowest parasitemia counts were found in rhesus monkeys of Bur-
mese origin, resulting in low oocyst counts, as well. Monkeys of
Indian or Chinese origin yielded better results. The number of
sporozoites was weakly positively correlated with oocyst counts
from feed 1 (Spearman’s rho, 0.398; P 0.0062) (see Fig. S1B in
the supplemental material). The positive correlation between par-
asitemia and oocyst number is also found for feed 2 (at day 12 after
rhesus infection), albeit weaker (Spearman’s rho, 0.37; P 
0.0092) (see Fig. S1C in the supplemental material). The correla-
tion coefficient between sporozoite yield and oocyst number (see
Fig. S1D in the supplemental material) for feed 2 is 0.51 (P 
0.0017). A subset of sporozoites from the 53 mosquito feeds was
used for the assays described below.
P. cynomolgi liver stage parasites develop to full maturity in
vitro, with small liver stage parasites resembling hypnozoites
remaining. Freshly isolated primary rhesus hepatocytes from
different monkeys were used for in vitro sporozoite infections
(Fig. 1A). Hepatocytes were incubated with freshly dissected
sporozoites, resulting in variable numbers of EEFs. Infected-
cell numbers ranged from 0.09 to 3.0% (observations from 16
successful assays) (see Fig. S2 in the supplemental material).
No clear correlation could be established between the back-
grounds of hepatocyte donors and hepatocyte quality, but cell
quality (visual evaluation involved cell density, granulation,
and shape) played a role in sporozoite permissiveness, as EEF
counts were reduced in visibly unhealthy cells. To follow EEF
development over time, P. cynomolgi sporozoite-infected hepa-
tocytes were fixed at several time points after infection and stained
with anti-HSP70 antibodies (Fig. 1B). From day 5 postinfection
(p.i.), two populations of parasites began to emerge, consisting of
small forms that remained at the size of3-day-old parasites (7
m) and a population of heterogeneously sized schizonts. At day
10 p.i., we could observe small forms that had remained small (Fig.
1B and P to R), as well as free merozoites (Fig. 1B and M to O).
Incubation of RBCs with merosomes from the in vitro liver stage
FIG 1 In vitro liver stage assay, intracellular development of P. cynomolgi, and PVM staining of small EEFs. (A) Schematic representation of the P. cynomolgi in
vitro liver stage assay workflow. The experiment starts with the infection of a rhesus monkey with blood stage parasites from thawed stock. Mosquitoes are fed on
the parasitized rhesus blood around peak parasitemia. Salivary gland sporozoites are harvested14 days after the infected blood meal to infect primary rhesus
hepatocytes. After sporozoite invasion, compounds are added in a concentration series, and the assay mixtures are incubated for 6 days. Parasites are visualized
by staining Hsp70 with fluorescent antibodies. Small and large liver stage parasites are differentially counted using a high-content imager, resulting in a
dose-response curve. (B) Sporozoite-infected primary rhesus hepatocytes were fixed 1, 3, 5, 8, or 10 days after inoculation with P. cynomolgi sporozoites. Nuclei
were stained with 4=,6-diamidino-2-phenylindole (DAPI) (left column). Parasites were stained with anti-Hsp70 antibodies and fluorescein isothiocyanate
(FITC)-labeled secondary antibodies (middle column). An overlay is shown in the right column. Within 24 h after infection, intracellular parasites are visible
(images A to C), containing one nucleus (image A). The growth rates of all intracellular parasites appear to be similar until day 3 (images D to F). After 5 (images
G to I) and 8 (images J to L) days of intracellular development, schizonts and hypnozoite forms (arrowhead) can be distinguished. Approximately 53% of the EEFs
develop into mature schizonts, and 47% of the parasites remain small for the duration of the assay. Ten days after sporozoite inoculation, in the same well, free
merozoites were observed (images M to O), as well as persistent small forms with a single nucleus (P to R). The developing liver stage parasites grow out to full
maturity in a similar time frame, as reported in vivo (51). (C) Etramp staining of P. cynomolgi liver stage parasites. A liver schizont and a hypnozoite form
(arrowheads) are seen in this field. Images: A, nuclei of P. cynomolgi-infected primary rhesus hepatocytes stained with DAPI; B, mouse anti-Hsp70/anti-mouse
FITC staining ofP. cynomolgi liver stage parasites; C, PVM stained with rabbit-anti-P. cynomolgiEtramp/anti-rabbit-tetramethyl rhodamine isocyanate (TRITC),
showing the presence of a PVM in both parasites; D, merge of images A, B, and C. The presence of a PVM indicates that small EEFs are not the product of an
aborted in vitro invasion but, rather, that the parasites have successfully invaded the hepatocyte.
Zeeman et al.
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cultures did not result in P. cynomolgi-infected RBCs, probably
because of the parasite’s preference for reticulocytes. The small,
uninucleate, persistent EEFs are likely to be hypnozoites, as was
also noted by Hollingdale et al. (23), as well as Dembele et al. (21),
who showed differential drug sensitivity of these forms. Further
proof that the small forms we observed are indeed hypnozoites
was recently provided by Dembele et al. (25), who showed that the
small forms can reactivate in vitro. The small EEFs we therefore
call hypnozoite forms can be positively stained for P. cynomolgi
Etramp, a protein known to localize to the parasitophorous vacu-
ole membrane (PVM) of EEFs (34) (Fig. 1C). This indicates that
small EEFs are not the product of an aborted in vitro invasion but
have successfully invaded a hepatocyte and formed a PVM.
A reproducible drug assay platform allows testing of anti-
hypnozoite activity. With a view to developing a higher-through-
put drug assay than previously reported (21, 22), we amended the
assay described by Dembele et al. (21) by exposing EEFs to com-
pounds immediately after sporozoite invasion and incubating
them until day 6, rather than from days 5 to 8. In addition, we
implemented an automatic high-content imaging readout. To val-
idate the new assay, we infected monolayers of primary rhesus
hepatocytes with 50,000 P. cynomolgi sporozoites to which test
compounds were added approximately 3 h after sporozoite inoc-
ulation. Six days after sporozoite infection, the plates were fixed
and stained with anti-P. cynomolgi Hsp70 antibodies. Small and
large EEFs were separately counted, based on size and number of
parasite nuclei; 53% 	 12.7% (range, 28 to 74%) of the EEFs
consisted of developing liver stage parasites, independent of the
infection level of the cells, while 47%	 12.7% (range, 26 to 72%)
of the parasites remained small. Essentially, we observed drug sen-
sitivity profiles identical to those with the day 5 to 8 treatment
schedule described by Dembele et al. (21). More specifically, the
small, uninucleate EEFs were found to be susceptible only to PQ
and not to atovaquone (Fig. 2A) or pyrimethamine, similar to
hypnozoites, and are different from developing EEFs, which are
killed by all 3 drugs.
Collectively, these data show the presence of hypnozoite forms,
both by appearance and in the drug sensitivity profile. Further
support for the presence of hypnozoites in culture comes from
comparison to an in vivo drug test in a P. cynomolgi sporozoite-
infected rhesus monkey. The monkey was treated with atova-
quone for 6 days, starting immediately after sporozoite injection,
similar to the in vitro drug assay. While an untreated control mon-
key developed primary blood stage parasitemia on day 9, the
atovaquone-treated monkey developed blood stage parasitemia
only on day 19, at the time of the first relapse of the untreated
animal. Thus, in vitro, only hypnozoite forms remain after atova-
quone treatment, and in vivo, such parasites reactivate and cause
malaria relapse. Recently, these observations were further sub-
stantiated by Dembele et al., who showed in vitro reactivation of
hypnozoite forms in atovaquone-treated P. cynomolgi cultures
(25).
To assess the robustness of the in vitro drug assay, we per-
formed 10 independent PQ IC50 determinations. Assays were per-




FIG 2 P. cynomolgi liver stage drug assay validation. (A) Atovaquone sensitivity profile of large EEFs and hypnozoite forms. Three independent atovaquone IC50
assays were averaged and are shown here (	 standard deviations [SD]) with representative images of assay wells. Developing EEFs are more sensitive to the
compound than hypnozoite forms. At higher atovaquone concentrations, only small parasites are visible. (B) Reproducibility of the primaquine IC50 assay. Ten
independent P. cynomolgi primaquine in vitro liver stage drug assays were performed. IC50s were determined for individual assays and plotted. Indicated are the
mean values and the 95% confidence intervals. IC50s from the same experiment for schizonts and hypnozoite forms are indicated with identical symbols. Note
that the IC50 for hypnozoite forms is always higher than for schizonts within a single assay.
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formed with independent hepatocyte and sporozoite batches us-
ing independent PQ dilutions. The mean IC50 for PQ was 0.374
M (range, 0.036 to 5.780M) for developing liver stage parasites
and 0.839 M (range, 0.043 to 10.924 M) for hypnozoite forms
(Fig. 2B). We attributed the significant assay-to-assay variation of
PQ IC50s to variability of the primary hepatocytes used in the
assay. PQ is converted to an active metabolite and thus may be
affected by hepatocyte viability and the presence of active cyto-
chrome P450.
Evaluators blinded to reference compounds with known anti-
blood stage and/or anti-liver stage activity evaluated them in a
three-point, 10-fold-dilution fingerprinting series. The data are
largely in agreement with what is known of their antimalarial ac-
tivities (Table 1). Anti-blood stage compounds, like chloroquine
and artesunate, did not show any significant anti-EEF activity. On
the other hand, 8-aminoquinolines, known to prevent relapses in
vivo, were all active against hypnozoite forms and schizonts (Table
1). They included PQ; NPC1161B (35); tafenoquine, currently in
clinical trials (36); and bulaquine, also currently in clinical trials
(37–41). Atovaquone was the only compound tested that specifi-
cally inhibited developing EEFs to a high degree without affecting
hypnozoite forms. Cycloheximide, a protein biosynthesis inhibi-
tor, showed dose-dependent inhibition of developing EEFs, as
well as a limited effect on hypnozoite forms, but only at the highest
dose tested. This suggests that low-level protein biosynthesis may
be ongoing in the small, persistent liver forms. However, at the
highest cycloheximide dose, hepatocyte viability may have been
compromised due to its general toxicity, even though we did not
observe significant hepatocyte loss based on nucleus counts. This
may also have contributed to reduced numbers of hypnozoite
forms. All reference drugs displayed the expected activity pattern
on liver stages, suggesting a strong predictive value of this in vitro
liver stage/hypnozoite form drug assay.
Small-scale screening of malaria box compounds (prese-
lected compoundswithbloodstage activity) identified anewpo-
tent anti-liver stage compound class. We screened 14 selected
compounds that previously showed activity against the malaria
blood and/or liver stage (42). These compounds were primary hits
or had been subject to some preliminary lead optimization. The
selection was based on diversity of chemical structure and oppor-
tunities to further modify the compounds. Compounds were ini-
tially screened in three-point 10-fold dilutions (see Table S2 in the
supplemental material). Interestingly, one of the compounds ac-
tive against developing liver stages, QN254, is a known dihydro-
folate reductase (DHFR) inhibitor (11). The fact that it was not
active against hypnozoite forms highlights the assay’s expected
ability to distinguish compounds that are active only against large
EEFs.
We focused on three different compounds, evaluating their
activities against P. cynomolgi hypnozoite forms. These com-
pounds were the spiroindolone KAE609, which displays subnano-
molar activity against P. falciparum and P. vivax blood stages (43);
the imidazolopiperazine KAF156, an optimized clinical candidate
that has low nanomolar activity against blood and liver stages (44);
and the imidazopyrazine KAI407 (Fig. 3A). KAI407 was derived
from a lead compound (imidazolopyridine, compound 1 in Table
2) identified in a high-throughput blood stage screen (42), which
also showed weak activity in an in vitro assay using P. yoelii sporo-
zoites and HepG2 cells (20). Introduction of a methyl group to the
amide nitrogen produced compound 2, which improved blood
stage activity nearly 100-fold but lost liver stage activity. By mod-
ification of both aryl appendages, we obtained compound 3, with
blood and liver stage activity. Chemical modifications of the 6,5-
heterocyclic core provided an activity breakthrough. Introducing
a nitrogen to the 5 position of the bicyclic core generated the imida-
zopyrazine KAI407 (compound 4), with good potency (IC50  100
nM) on both blood and liver stage parasites (Table 2).
To determine if liver stage activity on the rodent parasite would
predict activity against P. cynomolgi liver stages, a three-point 10-
fold dilution series was performed with KAE609, KAF156, and
KAI407 (Fig. 3B). Similar to what was previously reported for
rodent malaria liver stages (20), KAE609 showed no activity
against either P. cynomolgi developing liver stages or hypnozoite
forms. KAF156 was active only against developing liver stages, in
agreement with the known causal prophylactic activity of mem-
bers of these series, such as GNF179 (16). In contrast, KAI407
displayed activity against both P. cynomolgi developing liver stages
and hypnozoite forms, similar to PQ. Subsequent IC50 determi-
nations for the two liver stage-active compounds showed IC50s of
0.09 M for KAF156 and 0.64 M (0.86 to 0.42 M) for KAI407
on developing liver stages and 
10 M (no dose response) for
KAF156 and 0.69 M (0.84 to 0.55 M) for KAI407 on hypnozo-
ite forms (80 nM against P. yoelii in vitro EEFs). This is slightly
better than PQ, for which IC50s in the same assays were 1.3 M
(0.29 to 2.31 M) for developing liver stages and 1.8 M (3.27 to
0.33 M) for hypnozoite forms (Fig. 3C) (7). Overall, based on
activity testing of this limited series, there seems to be concor-
dance between the rodent malaria and P. cynomolgi liver stage
TABLE 1 Reference compounds evaluated in three-point 10-fold
dilution series on P. cynomolgi liver stages
Compound name
Activity againsta:
Hypnozoite forms Schizonts
Amodiaquineb  
Artesunateb  
Dihydroartimisinb  
Lumefantrineb  
Piperaquineb  
Chloroquineb  	
Doxycyclineb 	 	
Mefloquineb 	 
Proguanilb 	 
Atovaquonec  
Cycloheximided  
Primaquinee  
NPC-1161Bf  
Tafenoquinef  
Bulaquinef  
a Activities of compounds (reduction of parasite counts at 10 M) are represented as
follows:, 0 to 10%;	, 10 to 20%;, 20 to 70%;, 70 to 90%;,
90%. Of
the nonaminoquinoline antimalarials, only atovaquone reduced the number of
developing liver stage parasites by more than 90%. The nonspecific protein synthesis
inhibitor cycloheximide had a minor effect on the number of small and large liver stage
parasites at the highest concentration tested. All 8-aminoquinolines tested were active
in the P. cynomolgi in vitro assay, efficiently killing both schizonts and hypnozoite
forms.
b Reference compound had known blood stage activity.
c Reference compound had known blood and liver stage activity.
d Reference compound is a known protein synthesis inhibitor.
e Reference compound is an 8-aminoquinoline, used as a radical cure, active against
gametocytes and liver stages (including hypnozoites).
f Reference compound is an 8-aminoquinoline.
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activities, although activity on hypnozoite forms cannot be pre-
dicted.
In vivo causal prophylaxis mouse model. KAI407 as a lead
compound needs further optimization before in vivo efficacy eval-
uation can be done in the P. cynomolgi rhesus relapse model. We
thus could not yet evaluate the prophylactic and radical curative
activities of this compound in the rhesus model. Based on its abil-
ity to eliminate developing liver stages, analogous to atovaquone
and KAF156, we therefore further tested whether KAI407 could
prevent the establishment of blood stage parasitemia after sporo-
zoite inoculation in a causal prophylactic rodent model. Four
groups of four mice each were treated by oral gavage with 20 or
100 mg/kg KAI407, 2.5 mg/kg atovaquone, or vehicle only and
then infected with P. berghei ANKA luciferase sporozoites (32)
within 2 h of dosing. The vehicle-only group became blood stage
positive 5.75	 0.46 days p.i. The low-dose KAI407-treated group
(20 mg/kg) became blood stage positive at day 6.5	 0.53 p.i., and
neither the atovaquone-treated mice nor the 100-mg/kg KAI407-
treated mice became blood stage positive over 30 days of monitor-
ing, achieving 100% protection in the two groups (Table 3). Al-
though these data do not speak to its potential radical cure activity,
they demonstrate that KAI407 is active against malaria tissue
stages in vivo.
DISCUSSION
The quiescent nature of malaria hypnozoites in the livers of P.
vivax- or Plasmodium ovale-infected individuals represents a sig-
nificant challenge for malaria eradication. Hypnozoites are found
only in these two human malaria parasites and in a few nonhuman
primate malaria parasites, one of which is P. cynomolgi. Prima-
quine remains the only treatment option for P. vivax patients but
has potentially severe side effects and contraindications (for a re-
cent review, see reference 45). Bolstering the malaria pipeline with
new chemical entities that overcome the liabilities associated with
primaquine is now a top priority. Historically, P. cynomolgi-in-
fected monkeys were used for screening compounds to detect
hypnozoitocidal activity. A large screening effort (14) in which
hundreds of monkeys were treated with experimental compounds
only confirmed the potency of 8-aminoquinolines as radical cure
compounds. More recently, a compound from a different chem-
ical class, a 2-guanidino-4-oxoimidazoline derivative (19), was
found to cure relapsingP. cynomolgi infections in rhesus monkeys.
In vivo large-scale screens are currently ethically and financially
restricted. Moreover, they are extremely low throughput and
time-consuming, which explains the dearth of new chemical en-
tities with proven hypnozoitocidal activity. The development and
application of an in vitro assay that can assess activity against hyp-
nozoite forms can bridge the current gap between blood stage (P.
falciparum) and liver schizont (P. yoelii) active compounds and
the P. cynomolgi-infected rhesus monkey model. We chose P. cyn-
omolgi rather than P. vivax as a way to reliably access sufficient
numbers of sporozoites from a single parasite strain, which is cur-
rently not possible for P. vivax. Our data show that mosquito
FIG 3 P. cynomolgi drug assays with selected malaria box compounds. (A) Structure formulas of KAE609, KAF156, KAI407, and primaquine. (B) Three-point
10-fold dilution series (0.1, 1, and 10 M) on P. cynomolgi liver stage cultures. The percentage of untreated control is shown as a function of the compound
concentration. Differential counting of schizonts and hypnozoite forms was performed based on size and number of parasite nuclei. The results of one
representative assay are shown; assays were performed at least twice. KAE609 was not active against liver stage parasites and was therefore not taken forward for
IC50 determination. (C) IC50 determination for KAF156, KAI407, and primaquine. Drugs were tested in a 2-fold dilution series. The percentage of untreated
control is shown as a function of the compound concentration. Differential counting of schizonts and hypnozoite forms was performed based on size and number
of parasite nuclei. IC50s were calculated based on fitted curves (nonlinear fit). The results of one representative assay are shown, and at least two independent assays were
performed. The activity of KAF156 is limited to schizonts, while KAI407 and primaquine also kill hypnozoite forms. The error bars indicate standard deviations.
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feeding on P. cynomolgi-infected rhesus monkey blood provides a
reliable source of sufficient numbers of sporozoites for in vitro
assays.
Time course immunofluorescence assay images of P. cynomolgi-
infected hepatocytes show uniform EEF development (based on
size and shape) until day 3 and two EEF populations emerging
after that, with 53% of schizonts progressing to merozoites by
day 10 and47% of EEFs remaining as small uninucleate forms,
essentially as previously described for in vivo-derived EEFs (46).
The persisting small EEFs share characteristics of hypnozoites,
including the morphologies derived from the limited description
of in vivo-derived hypnozoites (30, 31) and their atovaquone and
primaquine drug sensitivity profiles (21). Further evidence that
these in vitro-cultured small forms could indeed be hypnozoites
comes from our comparative in vivo drug treatment experiment,
in which we observed no primary blood stages in an atovaquone-
treated animal, which relapsed simultaneously with an untreated
animal. In vitro, liver schizonts were completely absent and only
small hypnozoite forms remained after atovaquone treatment.
Dembele (25) showed in long-term in vitro cultures that these
hypnozoite forms spontaneously started to develop into liver stage
schizonts after the atovaquone treatment was stopped. Collec-
tively, these data link the in vitro-cultured hypnozoite forms to the
appearance of relapse in vivo following initial atovaquone treat-
ment of infection and thus strengthen the case for in vitro-cul-
tured hypnozoites. Additionally, despite the small sample size of
in vivo prophylactic atovaquone-treated animals, the outcome
corroborates occasional clinical observations of P. vivax and P.
ovale infections in travelers, despite atovaquone/proguanil pro-
phylaxis (47). When taken together with our in vitro data, this
suggests that atovaquone is effective against the early developing
liver stage forms destined to become primary hepatic schizonts
but ineffective against the forms destined to become latent hyp-
nozoites. Thus, when prophylaxis is discontinued, relapses are
likely to occur.
Adaptations to the original in vitro model (21) were necessary
in order to allow larger-scale in vitro compound screening. The
implemented adaptations were (i) culture times reduced from 8 to
6 days to increase throughput; (ii) exposure to compounds con-
tinuously from day 0 to day 6 rather than from days 5 to 8 (here,
we found that shorter exposure to primaquine reduced assay sen-
sitivity, so we did not decrease the assay time any further); (iii)
replacement of manual readout by automated high-content im-
aging, which dramatically increased assay throughput. We used
the adapted assay to screen (blinded) a number of reference com-
pounds and identified a number of active compounds, which were
all 8-aminoquinolines known to prevent in vivo relapses, suggest-
ing good predictive value of the assay for activity against day 0 to 6
hypnozoites.
In an initial (blinded) small-scale screen of selected antimalar-
ial compounds (some of which had already been subjected to lead
optimization), we confirmed the reported activities on rodent ma-
laria liver stages in P. cynomolgi liver stages: the spiroindolone
KAE609 showed no activity against P. cynomolgi liver stages, while
the imidazolopiperazine KAF156 was active against P. cynomolgi
liver stages (20, 48). Like atovaquone, KAF156 affected only de-
veloping liver stages in a dose-dependent manner and had no
activity on hypnozoite forms.
With the modified drug treatment schedule, starting immedi-
ately after invasion, it became possible to identify different drug
sensitivities of the liver stage parasites. We believe this difference
reflects commitment of the sporozoites to become either a hypno-
zoite or a proliferative liver stage schizont at a very early time
point. The very early hypnozoite is relatively insensitive to all
drugs tested, showing reduced sensitivity to primaquine in com-
parison to developing parasites. This includes resistance to atova-
TABLE 2 Lead optimization toward KAI407a
Compound Structure
EC50
b (M)
Pf NF54
blood stage
P. yoelii
liver EEFs
1 5.59 6.35
2 0.052 
10
3 0.014 5.36
4 (KAI407) 0.081 0.088
a KAI407 was derived from lead compound 1, identified in a high-throughput blood
stage screen, which also showed weak activity in an in vitro assay using P. yoelii
sporozoites and HepG2 cells. Introduction of a methyl group to the amide nitrogen
provided compound 2 and improved blood stage activity nearly 100-fold, but lost liver
stage activity. By modification of both aryl appendages, we obtained compound 3, with
blood and liver stage activity. Chemical modifications of the 6,5-heterocyclic core by
introducing a nitrogen to the 5 position of the bicyclic core generated the
imidazolopyrazine KAI407 (compound 4) with good potency (IC50 100 nM) on both
blood and liver stage parasites.
b EC50, 50% effective concentration.
TABLE 3 Causal prophylaxis activity of KAI407 in an in vivo rodent
malaria model using P. berghei
Compound Dosea (mg/kg) Survival (%)
Prepatent periodb
(days	 SD)
Vehicle (untreated) 0 5.75	 0.46
Atovaquone 2.5 100 NAd
KAI407c 20 0 6.5	 0.53
KAI407c 100 100 NAd
a A single dose was administered via oral gavage 1–2 h prior to P. berghei sporozoite
infection.
b Average number of days before blood-stage parasitemia was detected by microscopy.
c Formulated in 0.5% (wt/vol) methylcellulose, 0.1% (vol/vol) Tween 80.
d NA, not applicable; 100% prophylaxis achieved.
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quone, a licensed causal prophylaxis against P. falciparum (49). In
contrast, the developing parasite population is sensitive, at similar
concentrations, to anti-liver stage antimalarials (atovaquone and
KAF156) that block P. yoelii from growing in hepatocytes. This
suggests that commitment to the hypnozoite developmental path-
way occurs early on, before, during, or immediately after infection
of the hepatocyte. Despite this early commitment, parasites des-
tined for the two pathways have indistinguishable rates of growth
up to day 3. After 3 days of development, clear morphological
differentiation of hypnozoites and developing liver stage parasites
becomes evident. Thus, parasites committed to a period of dor-
mancy require a period of growth subsequent to invasion before
entering latency.
Whether, immediately subsequent to day 3, parasites have al-
ready entered a dormant state that can be reactivated is as yet
unclear. In our hands and with our P. cynomolgi strain, the earliest
relapse observed in vivo (in an animal that was treated with atova-
quone from days 0 to 6 p.i. to kill all the primary liver stages) with
this P. cynomolgi strain occurred 19 days p.i. In addition, another
animal treated with chloroquine from days 14 to 16 to cure the
primary blood stage parasitemia relapsed by day 21 p.i. Chloro-
quine treatment may have delayed the appearance of blood stage
parasites in this animal. Assuming that (i) blood stage parasites
detected at day 19 are caused by merozoites directly emerging
from the liver (a reasonable assumption, because the animals were
infected with over 6 million sporozoites, leading to a large liver
load) and (ii) reactivated hypnozoites need 6 further days of de-
velopment before merozoites are released, reactivation of hypno-
zoites in vivo could start around day 13 p.i. This suggests the pos-
sibility that, for a period between days 3 and 13 post-hepatocyte
infection, further hypnozoite development may be required until
a reactivation-competent parasite is established. Under our cur-
rent assay format, both of the early stages (days 0 to 3 of treatment)
that are committed to hypnozoite development but are indistin-
guishable from nonlatent forms and those that have engaged in a
morphologically distinguishable hypnozoite-specific develop-
mental pathway (days 4 to 6 of treatment) are analyzed for drug
sensitivity. However, further research is needed to better under-
stand hypnozoite development and to determine whether there is
a period of development during which the hypnozoite-committed
lineage cannot be activated.
In a focused hit-to-lead effort, we identified a series of blood
stage-active compounds that were optimized for activity against
rodent liver stages. For one compound, KAI407, the liver stage
activity against rodent parasites translated into activity on both P.
cynomolgi developing EEFs and hypnozoite forms. This com-
pound displayed an activity profile identical to that of primaquine
in the same assay. Interestingly KAI407 activity was less variable
between assays than primaquine, suggesting a different metabolic
pathway or mode of action, as conversion to an active metabolite
does not seem to be required for activity (KAI407 is stable in the
presence of liver microsomes). The 100% protection of mice by a
single oral dose of 100 mg/kg KAI407 indicates that the compound
is active as causal prophylaxis against P. berghei,and is an interest-
ing candidate for causal prophylaxis against P. vivax-type para-
sites.
The exciting potential of the in vitro P. cynomolgi liver stage
drug assay, as well as the newly discovered compound, is clear.
Like primaquine, the newly discovered compound eliminated the
early hepatic stages destined to become the latent hypnozoites.
However, further optimization of theP. cynomolgi liver stage assay
and miniaturization to increase the throughput are required be-
fore screens of larger, more chemically diverse libraries can be
achieved. Improved hypnozoite cultures will permit more detailed
study of hypnozoite biology, including work to identify reactiva-
tion triggers (50). More detailed investigation of the antirelapse
properties of the KAI407 series of compounds as a critical step to
determining their clinical potential will require assessment in vivo.
KAI407 is currently the focus of a lead optimization effort to pro-
vide compounds suitable for testing in P. cynomolgi-infected rhe-
sus monkeys for prophylactic and antirelapse activities, the gold
standard for identifying antirelapse compounds. The outcome of
such an in vivo experiment will be an important next step in the
further validation of the in vitro P. cynomolgi liver stage drug assay
and the discovery and further development of new antirelapse
drugs for clinical use.
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